RxDoctor Payments DataLook up a doctor →

Jennifer Barbosa

Nurse Practitioner · Scottsdale, AZNPI 1770086456

Payments from drug & device makers

$20,573in general payments, 2019–2025

Across 813 payments — averaging $25.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Daiichi Sankyo Inc.$2K
  • AstraZeneca$2K
  • Novartis$1K
  • Johnson & Johnson$956
  • Pfizer$878
  • Seagen Inc.$869
  • plus $13K from 54 others

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Daiichi Sankyo Inc.19$1,728
AstraZeneca(2 entities)51$1,715
Novartis59$1,032
Johnson & Johnson(2 entities)32$956
Pfizer46$878
Seagen Inc.32$869
Astellas Pharma US Inc26$812
CTI Biopharma Corp.3$742
Bristol Myers Squibb52$716
Incyte Corporation21$609
Genentech USA, Inc.18$600
E.r. Squibb & Sons, L.L.C.22$518
Gilead(2 entities)21$510
Merck27$500
Sanofi24$462
Rigel Pharmaceuticals, Inc.17$438
Bayer22$425
AbbVie25$415
Amgen25$397
Eisai Inc.21$395
Pharmacyclics LLC, An Abbvie Company20$371
Ipsen Biopharmaceuticals, Inc12$371
AVEO Pharmaceuticals, Inc.11$361
Blueprint Medicines Corporation14$337
GSK13$317
Beigene USA, Inc.10$302
Puma Biotechnology, Inc.11$265
Takeda Pharmaceuticals U.S.A., Inc.9$247
Regeneron Healthcare Solutions, Inc.8$231
Sobi, Inc7$199
Mirati Therapeutics, Inc.10$180
Jazz Pharmaceuticals Inc.7$173
Array Biopharma Inc10$160
EMD Serono, Inc.7$149
Myovant Sciences Inc.8$144
Karyopharm Therapeutics Inc.7$135
Progenics Pharmaceuticals, Inc.1$125
Lilly USA, LLC8$117
Genmab U.S., Inc.1$113
Tersera Therapeutics LLC4$106
Taiho Oncology, Inc.4$104
Adaptive Biotechnologies Corporation5$96
Stemline Therapeutics Inc.5$84
Springworks Therapeutics, Inc.4$77
Servier Pharmaceuticals LLC3$74
Sun Pharmaceutical Industries Inc.3$73
ADC Therapeutics America, Inc.3$72
Dova Pharmaceuticals4$69
Exelixis Inc.3$67
Morphosys, US Inc.4$65
G1 Therapeutics, Inc.3$63
Clovis Oncology, Inc.3$58
Deciphera Pharmaceuticals Inc.3$57
Boehringer Ingelheim2$54
Coherus Oncology, Inc.2$50
Global Blood Therapeutics, Inc.3$44
Organon3$42
Sumitomo Pharma America, Inc.2$40
Chiesi USA, Inc.2$38
Fennec Pharmaceuticals, Inc.1$34

How this compares

$20,573 in reported general payments places this provider in the 95th percentile of 1,719 nurse practitioner providers in Arizona.

See all nurse practitioner providers in Arizona →

Medicare billing

Part B allowed, 2024
$46,196
Medicare patients
271
Services billed
909

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other nurse practitioner in Scottsdale

See the full list for Arizona →

Where these figures come from

Is this you, or does something look wrong? →